Overview
The Twist is Sequel Med Tech's tubeless patch insulin pump, FDA-cleared in 2024 for both Type 1 and Type 2 diabetes. It competes directly with the Omnipod 5 in the growing tubeless pump segment, but differentiates through its industry-lowest published occlusion rate and a proprietary SteadyFlow™ cannula design that maintains consistent insulin delivery regardless of body position or physical activity.
Tubeless patch pumps eliminate the external tubing that connects traditional pumps to the infusion set — a major source of kinking, disconnection, and accidental dislodgement. Twist's on-body design is discreet, waterproof, and designed to be worn during swimming, sports, and sleep without the lifestyle compromises of tubed pumps.
Founded by veterans of Insulet Corporation (makers of Omnipod), Sequel's leadership team has direct experience scaling the tubeless pump category from early adoption to mainstream — giving the company strong commercial credibility with endocrinologists and diabetes care specialists.
Key Technology
🎯
SteadyFlow™ Cannula
Patented cannula geometry maintains consistent flow angle regardless of body movement or posture — addressing the primary mechanism behind occlusion events in patch pumps.
📡
Tubeless Wireless Design
No external tubing. Controller communicates with the on-body pod wirelessly. Pod is worn discreetly and changed every 3 days.
💧
Waterproof (IPX8)
Rated for submersion up to 7.6m for 60 minutes. Patients can swim, shower, and participate in water sports without removing the pump.
🔗
AID System Ready
Designed with open integration architecture for future closed-loop AID partnerships with CGM manufacturers and AID algorithm developers.
Indications & Comparison
Type 1 Diabetes
Type 2 Diabetes (Insulin-Requiring)
CSII Therapy
Ages 2+ Years
Key Differentiator
Lowest Published Occlusion Rate in Patch Pump Category
Sequel's pivotal trial demonstrated occlusion rates significantly below published rates for Omnipod 5 and Omnipod DASH, the primary clinical rationale for clinician interest in switching patients.
Founder Advantage
Insulet Veteran Leadership
CEO and core team are former Insulet executives who built Omnipod into a multi-billion dollar platform — bringing deep commercial, regulatory, and reimbursement expertise to the launch of Twist.
Timeline
2020
Sequel Med Tech founded by Insulet alumni; Series A financing
2022
Pivotal clinical trial initiated; SteadyFlow™ cannula patent filed
2024
FDA 510(k) clearance for T1D and T2D; commercial launch in US
2025
Growing commercial adoption; payer coverage negotiations advancing; AID partnership in development